ATL Partners Announces Sale of Geost to Rocket Lab and Launches New Defense Electronics Platform, Trident Solutions
NEW YORK, May 27, 2025--(BUSINESS WIRE)--ATL Partners ("ATL"), a sector-focused private equity firm, today announced the sale of Geost, LLC ("Geost"), a subsidiary of its portfolio company LightRidge Solutions, to Rocket Lab USA, Inc. (Nasdaq: RKLB), a leading space systems and launch services provider. This transaction represents a successful exit for ATL, which acquired Geost in 2021 and, in partnership with management, scaled the business into a market leader in electro-optical and infrared (EO/IR) sensing technologies supporting high-priority national security space missions.
With more than 20 years of flight heritage across classified and unclassified missions, Geost delivers advanced EO/IR sensor systems for missile warning and tracking, tactical intelligence, surveillance and reconnaissance, Earth observation, and space domain awareness – core capabilities for achieving the U.S. Department of Defense's goals for resilient, proliferated space architectures such as the proposed Golden Dome.
ATL takes a thematic approach to investing and is focused on three critical, high-growth and attractive segments of the industrial economy: commercial aerospace, national security, and transportation & logistics. Accordingly, in 2021, ATL established LightRidge Solutions as a platform to acquire national security-focused assets following the acquisition of Geost.
Under ATL's ownership, Geost entered new critical mission areas, introduced innovative and affordable products for its customers, and expanded its production and engineering base to be a leading supplier of payloads. Rocket Lab's acquisition affirms the value and technical excellence Geost brings to the EO/IR payload space and meaningfully enhances Rocket Lab's integrated solutions for defense and intelligence customers.
"Under ATL's ownership, Geost has been transformed into a disruptive and innovative space technology business," said Michael Kramer, a Partner at ATL Partners. "We have worked closely with Geost's talented team to accelerate growth, deepen technical capabilities, and expand customer engagement. Geost's contributions to missile warning, space domain awareness and protection, and proliferated LEO architectures have been fundamental to this success. Rocket Lab is a compelling new home for Geost's team and mission, and we are excited to see what comes next."
Bill Gattle, Geost's General Manager and CEO of LightRidge Solutions, said, "We are incredibly grateful to ATL Partners for its support and strategic guidance over the past four years. With ATL's backing, we have grown into an industry leader, delivering technologies that address real mission needs for government and commercial customers. By joining forces with Rocket Lab, we are enhancing our ability to scale, accelerate innovation, and broaden our impact. We look forward to this next chapter as we continue to meet the evolving challenges of our customers and the industry."
ATL Launches Trident as a Defense Electronics Platform
Upon the closing of this transaction, ATL will combine the two remaining divisions of LightRidge, Trident Systems and Ophir Corporation, to form a newly integrated platform, Trident Solutions. This new entity will focus exclusively on providing mission critical electrical components, processing solutions, and airborne payloads that are aligned with the country's most pressing national security challenges. ATL believes that Trident Solutions is well positioned to serve as a partner of choice for many leading prime and government customers across multiple domains as well as capitalize on growing opportunities in defense electronics, national security space, and advanced airborne systems. ATL Partners will continue to actively support Trident Solutions as it expands its platform through both organic growth and strategic acquisitions.
The transaction is subject to regulatory review and approval which is expected to be obtained in the second half of 2025. LightRidge and Rocket Lab will operate as independent businesses and run their operations as usual until that time.
Baird served as financial advisor and Gibson, Dunn & Crutcher LLP served as legal counsel to LightRidge.
About ATL Partners:
Founded in 2014, ATL Partners is a premier sector-focused private equity firm that invests in commercial aerospace, national security, and transportation & logistics companies. ATL brings deep sector expertise to its investment approach with experienced investment professionals and strong operating executives who have decades of combined experience in each of ATL's core sectors. For more information about ATL Partners, visit https://www.atlpartners.com.
About Geost
Founded in 2004, Geost, LLC, a LightRidge Solutions Company and portfolio company of ATL Partners, is a rapidly growing producer of affordable high-performance optical systems for critical national security space missions. The company has served its core National Security Space customer base since its founding and employs over 100 high performing professionals. For more information on Geost visit: https://www.geost.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526875032/en/
Contacts
Media: Nathaniel Garnick/Justin DechiarioGasthalter & Co.(212) 257-4170
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
WISeKey to Present at Maxim Tech Conference 'Discover the Innovations Reshaping Tomorrow' on June 3 at 8:30am ET
WISeKey to Present at Maxim Tech Conference 'Discover the Innovations Reshaping Tomorrow' on June 3 at 8:30am ET Geneva, Switzerland, June 2, 2025 –WISeKey International Holding Ltd ('WISeKey') (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its management team will be presenting at the Maxim Group 2025 Virtual Tech Conference 'Discover the Innovations Reshaping Tomorrow.' WISeKey's fireside chat presentation is scheduled for June 3rd at 8:30 am ET. Investors can access the live presentation via the following link: During the presentation, Carlos Moreira, WISeKey's Founder and CEO, will provide a progress update on WISeKey's platform as it advances through the 'Year of Convergence,' integrating its subsidiaries' cybersecurity offerings: (WISeID) digital identification, (SEALSQ) post-quantum technology, (WISeSAT) satellite constellation, and (SEALCOIN) tokenization projects into the Company's revenue stream. About WISeKey WISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@
Yahoo
34 minutes ago
- Yahoo
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS). The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4). 'We are pleased to bring our potential best-in-class GLP-2 analog, glepaglutide, one step closer to patients in Europe living with short bowel syndrome with intestinal failure, who urgently need more effective and more convenient treatment options,' said David Kendall, MD, Chief Medical Officer of Zealand Pharma. 'We believe that glepaglutide, administered twice weekly, offers meaningful potential to reduce both the burden of parenteral support and the inconvenience of daily dosing required with the only currently available GLP-2 therapy. Looking ahead, we expect to initiate the EASE-5 Phase 3 trial in the second half of the year to obtain further confirmatory safety and efficacy data on the twice weekly dosing regimen, supporting regulatory submission in the U.S.' About glepaglutideGlepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is developed as a liquid product in an autoinjector designed for subcutaneous administration by twice weekly dosing, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS. About the EASE Clinical Trial ProgramThe Phase 3 program, named EASE, is designed to evaluate the potential for glepaglutide to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure. EASE-1 (NCT03690206) was a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered twice weekly significantly reduced the total weekly volume of PS by 5.13 liters/week, compared to a reduction of 2.85 liters/week in the placebo group (p=0.0039). When administered once weekly, glepaglutide treatment resulted in a reduction in weekly PS of 3.13 liters/week, however this did not achieve statistical significance. A total of 9 patients treated with glepaglutide were completely weaned off PS (achieving enteral autonomy), while no placebo-treated patients were able to discontinue PS. For patients treated with glepaglutide twice weekly, 14% of patients (n=5) achieved enteral autonomy. In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the ongoing two-year, long-term safety and efficacy extension trial, EASE-2. EASE-2 (NCT03905707) is a randomized, double-blind trial in which SBS patients continued their randomly assigned treatment from EASE-1 with glepaglutide 10 mg once- or twice-weekly. Patients who received placebo in EASE-1 were re-randomized to treatment with either glepaglutide 10 mg once- or twice-weekly. In an interim analysis conducted after at least six months of treatment, clinical response to glepaglutide across the key efficacy endpoints was generally maintained or showed continued improvement, including additional patients on both doses weaning off PS. Patients who complete EASE-2 are eligible to participate in EASE-3 (NCT04881825), evaluating glepaglutide administered once weekly using an autoinjector. An interim analysis of EASE-3, conducted with the first 57 patients rolled over from EASE 2, showed that the reduction in prescribed PS was generally maintained. EASE-4 (NCT04991311) was a Phase 3b trial to assess mechanistic effects of glepaglutide on intestinal fluid and energy uptake. The trial provides evidence of the pharmacodynamic effects of glepaglutide in improving intestinal absorption. In the second half of 2025, Zealand Pharma expects to initiate EASE-5, a single Phase 3 clinical trial that is anticipated to provide further confirmatory evidence for a regulatory submission in the U.S. About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Forward looking statementsThis press release contains 'forward-looking statements', as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@ Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@ Anna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate Communicationsakrassowska@
Business Insider
3 hours ago
- Business Insider
China Liberal Education announces suspension of Nasdaq trading
China Liberal Education (CLEU) announced that on May 30, 2025, the Company received notice from The Nasdaq Stock Market LLC that the Company's securities will be suspended from trading on Nasdaq effective June 3, 2025. The suspension is due to the Company's failure to submit a request for an extended stay or otherwise address the delinquency in filing its annual report on Form 20-F for the fiscal year ended December 31, 2024, in its written submissions to the Nasdaq Hearings Panel. Confident Investing Starts Here:
